[{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"81518a0a-35de-4448-98f4-4a51c7a1c09f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05004974","created_at":"2021-08-13T12:53:34.296Z","updated_at":"2024-07-02T16:35:15.425Z","phase":"Phase 2","brief_title":"Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05004974","lead_sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","biomarkers":" TNFRSF9","pipe":" | ","alterations":" PD-L1 expression • FGFR1 mutation","tags":["TNFRSF9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/26/2022","start_date":" 04/26/2022","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-03-11"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"bbd1a478-a3ea-4485-aa56-e8b3f93758ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT01975701","created_at":"2021-01-18T08:59:44.203Z","updated_at":"2024-07-02T16:36:52.939Z","phase":"Phase 2","brief_title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM","source_id_and_acronym":"NCT01975701","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1","pipe":" | ","alterations":" FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation","tags":["FGFR2 • FGFR3 • FGFR1 • TACC3 • TACC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR3-TACC3 fusion • FGFR2 fusion • FGFR1 mutation • FGFR1 fusion • FGFR3 fusion • FGFR translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Truseltiq (infigratinib)"],"overall_status":"Completed","enrollment":" Enrollment 26","initiation":"Initiation: 12/09/2013","start_date":" 12/09/2013","primary_txt":" Primary completion: 10/03/2018","primary_completion_date":" 10/03/2018","study_txt":" Completion: 10/03/2018","study_completion_date":" 10/03/2018","last_update_posted":"2019-12-04"}]